Malignant tumor or benign cyst?

“Studies suggest women with ovarian cancer have better outcomes and increased survival when treated by surgeons trained in the management of ovarian cancer and at institutions specializing in the care of women with this disease,” adds Dr. Moore. “By using the combination of HE4 and CA 125 as a model to assess a women’s risk for ovarian cancer, physicians can better triage patients for care and refer them to the appropriate specialist – whether at a community hospital or large academic institution.”

“Together, HE4 and CA 125 offer a powerful combination that could dramatically change the way ovarian cancer is managed at all stages of care,” said Dr. Olle Nilsson, vice president and chief scientific officer of Fujirebio Diagnostics, the developers of the CA 125 test. “As research continues to progress, it is our hope that a test for HE4 and CA 125 could eventually lead to a plausible screening tool.”

Fujirebio Diagnostics has developed a manual test for HE4 and will be developing automated formats of the test for Fujirebio instruments. The HE4 test is CE marked in Europe. The company has applied to the U.S. Food and Drug Administration (FDA) and hopes to see availability of the test in late 2008.

About Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics, Inc. is a premier diagnostics company and the industry leader in biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is one of the group companies of Miraca Holdings Inc. in Japan, set up in July 2005 to combine Fujirebio Inc., the leading in-vitro diagnostics company, and SRL, Inc., the top provider of clinical laboratory testing services in Japan. Fujirebio Diagnostics has a worldwide distribution network, which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics, please call 610-240-3800 or visit www.fdi.com.

About Women & Infants Hospital

Women & Infants Hospital of Rhode Island, a Care New England hospital, is one of the nation’s leading specialty hospitals for women and newborns. The primary teaching affiliate of The Warren Alpert Medical School of Brown University for obstetrics, gynecology and newborn pediatrics, Women & Infants is the ninth largest obstetrical service in the country with more than 9,000 deliveries per year. In 2003, Brown University and Women & Infants were named a National Center of Excellence in Women’s Health by the U.S. Department of Health and Human Services. Women & Infants has been named one of the best hospitals in gynecology in the 2000, 2001 and 2004 editions of America’s Best Hospitals in U.S. News & World Report. For information about Women & Infants, log on to www.womenandinfants.org.